Cited by 14Nanoplatforms for cancer theranosticsAlzheimer's disease research and treatmentsMolecular Sensors and Ion Detection

Near-infrared II theranostic agents for the diagnosis and treatment of Alzheimer’s disease

Zhou, Can, Zeng, Fantian, Yang, Haijun, Liang, Zeying, Xu, Guanyu, Li, Xiao, Liu, Xingdang, Yang, Jian·2024·European Journal of Nuclear Medicine and Molecular Imaging

Abstract

Background Near-infrared II theranostic agents have gained great momentum in the research field of AD owing to the appealing advantages. Recently, an array of activatable NIR-II fluorescence probes has been developed to specifically monitor pathological targets of AD. Furthermore, various NIR-II-mediated nanomaterials with desirable photothermal and photodynamic properties have demonstrated favorable outcomes in the management of AD.Methods We summerized amounts of references and focused on small-molecule probes, nanomaterials, photothermal therapy, and photodynamic therapy based on NIR-II fluorescent imaging for the diagnosis and treatment in AD. In addition, design strategies for NIR-II-triggered theranostics targeting AD are presented, and some prospects are also addressed.Results NIR-II theranostic agents including small molecular probes and nanoparticles have received the increasing attention for biomedical applications. Meanwhile, most of the theranostic agents exhibited the promising results in animal studies. To our surprise, the multifunctional nanoplatforms also show a great potential in the diagnosis and treatment of AD.Conclusions Although NIR-II theranostic agents showed the great potential in diagnosis and treatment of AD, there are still many challenges: 1) Faborable NIR-II fluorohpores are still lacking; 2) Biocompatibility, bioseurity and dosage of NIR-II theranostic agents should be further revealed; 3) New equipment and software associated with NIR-II imaging system should be explored.

Integrity signals

Registry

Crossref · 10.1007/s00259-024-06690-1

Cites

96 of 96 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The majority of reported NIR-II organic small-molecule fluorophores incorporate one or more of these core scaffolds.

    “Indeed, the majority of reported NIR-II organic small-molecule fluorophores incorporate one or more of these core scaffolds73,74.”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Zhou, C., Zeng, F., Yang, H., Liang, Z., Xu, G., Li, X., Liu, X., & Yang, J.
Affiliations
  • Shanghai University (CN)
  • Xiamen University (CN)
  • Chinese Academy of Sciences (CN)
  • Fudan University (CN)
Corresponding author
  • Li, Xiao
  • Liu, Xingdang
  • Yang, Jian
Venue
European Journal of Nuclear Medicine and Molecular Imaging
Published
2024-03-19
Volume
51
Issue
10
Pages
2953-2969
ISSN
  • 1619-7070 (ISSN-L)
  • 1619-7089
OpenAlex
W4392956232
Cited by
14
References
96
Citations by year
2026: 1 · 2025: 11 · 2024: 2
FWCI
0.50
Type
journal article
Language
en
Open access
closed
Locations
  • European Journal of Nuclear Medicine and Molecular Imaging (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Physical Sciences › Chemistry › Spectroscopy › Molecular Sensors and Ion Detection
Keywords
Alzheimer's disease, theranostic agents, chemical probes, nanomaterials, photothermal therapy, photodynamic therapy, multifunctional nanoplatforms, Alzheimer's disease diagnosis, Alzheimer's disease treatment
MeSH terms
Theranostic Nanomedicine, Alzheimer Disease, Animals, Humans, Infrared Rays

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review